FAQ on Oragenics Inc.'s Manufacturing Partnership for Concussion Drug Phase IIb Trials

What is the significance of Oragenics Inc.’s partnership with Sterling Pharma Solutions?

The partnership is significant as it ensures the GMP production of ONP-002, Oragenics’ lead drug candidate for concussion, in the U.S., streamlining clinical development and regulatory progress for the upcoming Phase IIb trials.

What is ONP-002 and what condition does it target?

ONP-002 is Oragenics’ lead drug candidate designed to target mild traumatic brain injury (mTBI), also known as concussion, through intranasal delivery.

When are the Phase IIb trials for ONP-002 expected to begin?

The Phase IIb trials for ONP-002 are expected to begin next year, as part of Oragenics’ clinical development plan.

Where will the ONP-002 be manufactured?

ONP-002 will be manufactured at Sterling Pharma Solutions’ facility in Cary, North Carolina, under cGMP conditions.

Who is the CEO of Oragenics Inc. and what did they say about the partnership?

Janet Huffman is the CEO of Oragenics Inc. She described the partnership with Sterling Pharma Solutions as ‘a critical milestone’ that underscores the company’s dedication to U.S.-based innovation and quality.

How can I find more information about Oragenics Inc. and its drug candidates?

More information about Oragenics Inc. and its drug candidates can be found on the company’s website at www.Oragenics.com or in the company’s newsroom at https://ibn.fm/OGEN.

What other conditions is Oragenics Inc. targeting with its drug candidates?

Besides concussion, Oragenics Inc. is also developing drug candidates for treating Niemann Pick Disease Type C (NPC), along with proprietary powder formulation and an intranasal delivery device.

What is the role of InvestorWire in this announcement?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication, helping Oragenics Inc. reach a wide audience of investors, influencers, and the general public.